Vitiligo
Exam relevance: in 3 of more than 50 board exam reports · rank 45
- Synonyms
- white patches
- Specialty
- Dermatology · Pigmentation disorders
- Images
- Clinical 11
- In the app
- 4 flashcards
- Last updated
- 11/2026 · Dr. Pascal Bafteh
Contents
Images (11)











Definition
Vitiligo is an acquired, chronic pigmentary disorder. In circumscribed areas the melanocytes are destroyed and the skin loses its pigment completely. The result is sharply demarcated, milk- to chalk-white patches that do not scale and usually do not itch. Vitiligo is not contagious and not life-threatening, but it is not merely a cosmetic problem: it is a chronic autoimmune disease, and on visible skin the psychological burden is an important part of the disease. In 2020 the German Federal Joint Committee (G-BA) discontinued a procedure to add a vitiligo medicine to its list of “lifestyle drugs” excluded from statutory health insurance, stating there was currently no need for regulation.
Types
The international consensus (Vitiligo Global Issues Consensus Conference, 2012) distinguishes two main forms:
- Non-segmental vitiligo (usually just called “vitiligo”, about nine in ten cases): symmetrical patches on both sides of the body. Subtypes are acrofacial vitiligo (fingers, hands, around the mouth and eyes), generalised, universal (almost the entire skin) and mucosal vitiligo. The course comes in flares and is hard to predict.
- Segmental vitiligo: one-sided, in one or more segments, often on the face. It usually starts in childhood, spreads over a few months and then generally stops. White hairs within the patch are common.
In addition there is mixed vitiligo (segmental, later also non-segmental patches) and focal vitiligo, a single small patch that cannot yet be classified.
Occurrence
About 0.5 to 2 percent of people worldwide have vitiligo, women and men equally, in all skin types. It can start at any age; in about half of patients it appears before the age of 20. Roughly one in five affected people has a first-degree relative with vitiligo.
Causes
Vitiligo is regarded as an autoimmune disease in genetically predisposed people. Cytotoxic CD8 T cells recognise melanocyte antigens and destroy the pigment cells; interferon-γ signalling and the chemokine CXCL10 keep the process going. Melanocytes of affected people are also more vulnerable to oxidative stress. Genome-wide studies have found about 50 risk loci, many of them in immune genes.
Mechanical irritation can trigger new patches (Koebner phenomenon): at friction sites, over bony prominences, under belts or watch straps, after injuries.
Clinical features and course
Typical are milk-white, sharply and often convexly bordered patches without scale. Preferred sites are the skin around the mouth, nose and eyes, fingers and the backs of the hands, elbows, knees, armpits, groins and the genital area. Hairs within a patch can turn white as well (leukotrichia); this is considered an unfavourable sign for repigmentation. The patches sunburn easily.
Signs of active vitiligo, i.e. vitiligo that is spreading:
- Confetti-like depigmentation: many tiny white dots at the edge of or around existing patches.
- Trichrome vitiligo: a light-brown transition zone between the white patch and normal skin.
- Koebner phenomenon: new patches at sites of scratching, friction or injury.
- Inflammatory border: rarely a red, slightly raised rim.
When the skin regains colour, this usually begins with small brown dots around hair follicles or from the edge. The face and neck repigment more readily than hands, feet and trunk.
Associated diseases: The most common is autoimmune thyroiditis (Hashimoto’s, less often Graves’ disease). Less often alopecia areata, type 1 diabetes, pernicious anaemia, rheumatoid arthritis or Addison’s disease occur – mainly with non-segmental vitiligo.
Psychological burden: It is often underestimated. In a meta-analysis of 25 studies with 2,708 patients, about one in four had depression based on diagnostic codes, and about one third reported depressive symptoms on questionnaires. The odds of depression were about five times higher than in control groups (odds ratio ≈ 5). Asking about mood and daily life therefore belongs in every vitiligo consultation.
Diagnosis
The diagnosis is clinical. Helpful are:
- Wood’s lamp (UVA): the patches light up bright bluish-white with a sharp border. On fair skin this also reveals patches that are barely visible to the naked eye.
- Dermoscopy: absent or reduced pigment network, white hairs, perifollicular pigment islands during repigmentation; blurred borders and satellite lesions point to activity.
- Laboratory: TSH and anti-TPO antibodies to look for thyroid involvement; further tests (blood glucose, blood count, vitamin B12) according to symptoms and history.
- Biopsy: only if the picture is unclear. Histology shows absent melanocytes in the basal layer (immunohistochemistry with Melan-A or MITF).
For follow-up, photographs under the same conditions and scores such as the VASI (Vitiligo Area Scoring Index) are used.
Differential diagnosis
- Pityriasis versicolor: fine, bran-like scale when the patch is scratched, hypo- rather than depigmented; fungi on tape strip or KOH preparation.
- Pityriasis alba: ill-defined, lighter, slightly scaly patches on the face of children, often with atopic dermatitis.
- Post-inflammatory hypopigmentation: at sites of earlier inflammation, not milk-white, ill-defined.
- Naevus depigmentosus: present from birth or early childhood, only grows in proportion, hypopigmented rather than white.
- Piebaldism: congenital and stable, often with a white forelock.
- Lichen sclerosus: whitish in the genital area, but with parchment-like atrophy, itching and fissures.
- Chemical leukoderma: after contact with phenols or catechols (e.g. rubber, hair dyes), initially limited to the contact site.
- Hypopigmented mycosis fungoides, leprosy: rare; biopsy if sensation is reduced in the patch or the course is atypical.
Differential diagnoses
Pityriasis versicolor (tinea versicolor)
Oculocutaneous albinism
Hypomelanosis of Ito (incontinentia pigmenti achromians)
Pityriasis alba
Lichen sclerosus
Pinta (carate)
Image credits for the thumbnails
- Pityriasis versicolor (tinea versicolor): Sarahrosenau on Flickr.com, “Tinea versicolor1”, CC BY-SA 2.0, via Wikimedia Commons · CC BY-SA 2.0 · Source
- Oculocutaneous albinism: Janjacob, “Albino boy by JJ Hoefnagel”, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0 · Source
- Hypomelanosis of Ito (incontinentia pigmenti achromians): Trägårdh M, Thomsen CR, Thorninger R et al. (J Med Case Rep 2014), “Hypomelanosis of Ito presenting with pediatric orthopedic issues: a case report”, CC BY 2.0, via PubMed Central (PMC4077238) · CC BY 2.0 · Source
- Pityriasis alba: Siegfried EC, Hebert AA (J Clin Med 2015), CC BY 4.0, via PubMed Central (PMC4470205) · CC BY 4.0 · Source
- Lichen sclerosus: Frucht CS, Ragsdale BD, Cureus 2026, Figure 1, CC BY 4.0, via PubMed Central (PMC13614091) · CC BY 4.0 · Source
- Pinta (carate): Mitjà O, Šmajs D, Bassat Q (PLoS Negl Trop Dis 2013), photo F. Gómez (Mexico), CC BY 4.0, via PubMed Central (PMC3812090) – figure 2, panel E (cropped) · CC BY 4.0 · Source
Treatment principles
- Treatment is stepwise: localised disease is treated with topical glucocorticoids, preferably with calcineurin inhibitors or topical JAK inhibitors on the face and in the flexures.
- For extensive disease, narrowband UVB phototherapy is the treatment of choice, with the excimer laser for localised lesions; rapidly progressive disease is stabilised systemically.
- Surgical grafting techniques are an option for stable, segmental vitiligo; sun protection, camouflage and psychosocial support complement treatment.
Guideline: AWMF guideline register (no. 013-093)
Specific treatment regimens with drugs and doses are covered in the DermaFuchs app.
Keep learning in the app
References (selection)
- Ezzedine K, Lim HW, Suzuki T et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-13
- Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571-592
- Picardo M, Dell'Anna ML, Ezzedine K et al. Vitiligo. Nat Rev Dis Primers. 2015;1:15011
- Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621-648
- Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708-718
- Gemeinsamer Bundesausschuss. Tragende Gründe zur Einstellung des Verfahrens Anlage II (Lifestyle-Arzneimittel) – Ergänzung für das Anwendungsgebiet Vitiligo, 20.08.2020
Cross-references
Mentioned in
- Lichen sclerosus
- Pityriasis versicolor (tinea versicolor)
- Progressive macular hypomelanosis
- Halo naevus (Sutton naevus)
- Naevus depigmentosus (achromic naevus)
- Pityriasis alba
- Hypomelanosis of Ito (incontinentia pigmenti achromians)
- Oculocutaneous albinism
- Piebaldism
- Naevus anaemicus (nevus anemicus)
- Idiopathic guttate hypomelanosis
- Pinta (carate)
More pigmentation disorders
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the DermaFuchs app – free, in your browser or as an app.
Related pages: Pityriasis versicolor (tinea versicolor) · Naevus depigmentosus (achromic naevus) · Oculocutaneous albinism
Note: This page is intended for medical education and does not replace diagnosis or treatment decisions in individual cases.